Brief: Immixbio Announces Positive Imx-110 Phase 1B/2A Interim Clinical Trial Safety Data
19/01/2022 13:32
Jan 19 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIXBIO ANNOUNCES POSITIVE IMX-110 PHASE 1B/2A INTERIM
CLINICAL
TRIAL SAFETY DATA DEMONSTRATING 100% COMPLETION OF PLANNED
TREATMENT CYCLES
* IMMIX - 100% OF PATIENTS TREATED WITH IMX-110 COMPLETED
PLANNED
TREATMENT CYCLES WITHOUT DRUG-RELATED INTERRUPTIONS IN ONGOING
PHASE 1B/2A TRIAL
Source text for Eikon: ID:nGNX4fMJV6
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary